Lost password ?
<< Back to Equity Research
Dallah Healthcare
DALLAH HEALTHCARE GOES TOO SPICY
Oct 05 - In our last short paper of last March on Dallah Healthcare (Sell, Saudi Arabia), we have recommended investors to be cautious on the short term financial performance of Dallah and were proved right ...
Executive summary
Conflict of Interest
Pages 38
Language English
Publish on October 5, 2020
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 08 AM
Mouwasat Medical
Target pushed up by strong results
Mar 26 AM
Dallah Healthcare
Target boosted by a strong outlook
Mar 26 AM
Mouwasat Medical
Mouwasat Medical increases its net profit by 10%
Mar 15 AM
Dallah Healthcare
A slightly-weaker-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ